keyword
MENU ▼
Read by QxMD icon Read
search

Pegfilgrastim

keyword
https://www.readbyqxmd.com/read/28107322/on-body-injector-an-administration-device-for-pegfilgrastim
#1
Linda J Mahler, Regina DiBlasi, Anielka Perez, Jeannie Gaspard, Dayna McCauley
Many chemotherapy regimens used today require the support of a 
granulocyte-colony-stimulating factor for the prevention of 
life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta® (pegfilgrastim) through an on-body injector (Onpro®), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility...
February 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28105350/interstitial-pneumonia-following-administration-of-pegfilgrastim-during-carboplatin-and-etoposide-chemotherapy-for-small-cell-lung-cancer
#2
Masayuki Shirasawa, Yoshiro Nakahara, Hideyuki Niwa, Shinya Harada, Takahiro Ozawa, Seiichiro Kusuhara, Masashi Kasajima, Yasuhiro Hiyoshi, Jiichiro Sasaki, Noriyuki Masuda
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor formulation that has been approved for the prevention of febrile neutropenia. We herein report a case of interstitial pneumonia following administration of pegfilgrastim. A 65-year-old man with stage IV small-cell lung cancer was treated with carboplatin and etoposide as third-line chemotherapy. Pegfilgrastim was administered during the second cycle of chemotherapy. On the day after the administration of pegfilgrastim, interstitial pneumonia developed...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28097385/two-phase-1-dose-escalation-studies-exploring-multiple-regimens-of-litronesib-ly2523355-an-eg5-inhibitor-in-patients-with-advanced-cancer
#3
Jeffrey R Infante, Amita Patnaik, Claire F Verschraegen, Anthony J Olszanski, Montaser Shaheen, Howard A Burris, Anthony W Tolcher, Kyriakos P Papadopoulos, Muralidhar Beeram, Scott M Hynes, Jennifer Leohr, Aimee Bence Lin, Lily Q Li, Anna McGlothlin, Daphne L Farrington, Eric H Westin, Roger B Cohen
PURPOSE: This first-in-human report examined the recommended Phase 2 dose and schedule of litronesib, a selective allosteric kinesin Eg5 inhibitor. METHODS: Two concurrent dose-escalation studies investigated litronesib across the dose range of 0.125-16 mg/m(2)/day, evaluating the following schedules of administration on a 21-day cycle: Days 1, 2, 3; Days 1, 5, 9; Days 1, 8; Days 1, 5; or Days 1, 4, with or without pegfilgrastim. Best overall response was defined per Response Evaluation Criteria in Solid Tumors (RECIST Version 1...
January 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28038931/safety-of-same-day-pegfilgrastim-administration-in-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel-with-or-without-carboplatin
#4
Mehmet Asim Bilen, Diana H Cauley, Bradley J Atkinson, Hsiang-Chun Chen, Diana H Kaya, Xuemei Wang, Raghu Vikram, Shi-Ming Tu, Paul G Corn, Jeri Kim
INTRODUCTION: Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. PATIENTS AND METHODS: Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution...
December 13, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28038865/a-phase-iii-randomized-double-blind-placebo-controlled-trial-of-pegfilgrastim-in-patients-receiving-first-line-folfox-bevacizumab-or-folfiri-bevacizumab-for-locally-advanced-or-metastatic-colorectal-cancer-final-results-of-the-pegfilgrastim-and-anti-vegf-evaluation
#5
Tamás Pinter, Zandra Klippel, Alvydas Cesas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, Galina Kurteva, Jan Novotny, Seamus O'Reilly, Tomas Salek, Maureen Reiner, Phuong Khanh Morrow, Mi Rim Choi, Sadie Whittaker, Charles Blanke
BACKGROUND: Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind trial evaluated the efficacy of pegfilgrastim versus placebo in reducing the incidence of grade 3/4 FN in patients with advanced CRC receiving bevacizumab combined with first-line chemotherapy (FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin] or FOLFIRI [leucovorin, 5-fluorouracil, irinotecan])...
September 7, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27986205/costo-efectividad-del-uso-profil%C3%A3-ctico-del-factor-estimulante-de-colonias-de-granulocitos-en-adultos-con-leucemia-linfobl%C3%A3-stica-aguda-en-colombia
#6
Elkin Javier Casadiego Rincón, Jorge Augusto Díaz Rojas, Carlos Daniel Bermúdez, Víctor Prieto Martínez
OBJECTIVE: To assess the cost-effectiveness of prophylactic administration of Granulocyte Colony-Stimulating Factor (G-CSF) compared with no use of it, during the induction phase of chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) in Colombia. METHODS: A decision tree with a time horizon of 30 days was built under colombian health system perspective including only direct costs. The costs of procedures and medications were taken from official sources and an institution of national reference of oncology services...
December 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27983764/bendamustine-lenalidomide-and-dexamethasone-brd-has-high-activity-as-2-nd-line-therapy-for-relapsed-and-refractory-multiple-myeloma-a-phase-ii-trial
#7
Ulrich J M Mey, Wolfram Brugger, Heike Schwarb, Stefanie Pederiva, Andreas Schwarzer, Tobias Dechow, Paul Jehner, Jacqueline Rauh, Christian J Taverna, Mathias Schmid, Martin Schmidt-Hieber, Steffen Doerfel, Natalie Fischer, Axel Ruefer, Carsten Ziske, Wolfgang Knauf, Richard Cathomas, Roger von Moos, Felicitas Hitz, Rafael Sauter, Elke Hiendlmeyer, Nathan Cantoni, Mario Bargetzi, Christoph Driessen
The combination of lenalidomide (Revlimid(®) , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (VGPR)]. The combination of bendamustine (B), lenalidomide and dexamethasone (BRd) has shown high efficacy in patients with advanced rrMM. However, dose-limiting haematotoxicity restricted its use in extensively pre-treated patient populations...
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27928760/cost-effectiveness-analysis-of-prophylaxis-treatment-strategies-to-reduce-the-incidence-of-febrile-neutropenia-in-patients-with-early-stage-breast-cancer-or-non-hodgkin-lymphoma
#8
Kelly Fust, Xiaoyan Li, Michael Maschio, Guillermo Villa, Anju Parthan, Richard Barron, Milton C Weinstein, Luc Somers, Caroline Hoefkens, Gary H Lyman
OBJECTIVE: The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the incidence of febrile neutropenia (FN) in patients with stage II breast cancer receiving TC (docetaxel, cyclophosphamide) and in patients with non-Hodgkin lymphoma (NHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a lifetime horizon from a Belgian payer perspective...
December 7, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27904448/mobilization-with-cyclophosphamide-reduces-the-number-of-lymphocyte-subpopulations-in-the-leukapheresis-product-and-delays-their-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-multiple-myeloma
#9
Matevz Skerget, Barbara Skopec, Darja Zontar, Peter Cernelc
BACKGROUND: Autologous hematopoietic stem cell transplantation is considered the standard of care for younger patients with multiple myeloma. Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. The aim of our study was to investigate the differences in lymphocyte subpopulation counts between three different mobilization regimens on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27822615/g-csf-use-in-patients-receiving-first-line-chemotherapy-for-non-hodgkin-s-lymphoma-nhl-and-granulocyte-colony%C3%A2-stimulating-factors-g-csf-as-observed-in-clinical-practice-in-italy
#10
Umberto Vitolo, Francesco Angrili, Lucy DeCosta, Sally Wetten, Massimo Federico
Treatment of non-Hodgkin lymphoma (NHL) requires chemotherapy regimens with significant risk of febrile neutropenia (FN). For patients at ≥20% FN risk, guidelines recommend primary prophylaxis (PP) with granulocyte-colony stimulating factor (G-CSF). This study assessed whether G-CSF use in NHL was in line with recommendations in routine practice. This was a retrospective, observational study of adult NHL patients receiving first-line (R)CHOP-like chemotherapy and G-CSF support between June 2010 and 2012, in Italy...
December 2016: Medical Oncology
https://www.readbyqxmd.com/read/27819161/performance-of-the-pegfilgrastim-on-body-injector-as-studied-with-placebo-buffer-in-healthy-volunteers
#11
Rajeshree S Joshi, Ogo I Egbuna, Alex S Cairns, Michael J Friedman, Bassam Abosaleem, Maureen T Reiner, Phuong Khanh Morrow
OBJECTIVE: The pegfilgrastim on-body injector (OBI) is a single-use, disposable, battery-powered injector that is designed to automatically deliver a single subcutaneous dose of pegfilgrastim beginning approximately 27 hours after activation and continuing over approximately 45 minutes. In this open-label study, we assessed performance of the OBI delivering placebo buffer in healthy volunteers. RESEARCH DESIGN AND METHODS: Healthy men and women aged 18-55 years, with a body mass index of 18-35 kg/m(2), were enrolled...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27783280/optimal-primary-febrile-neutropenia-prophylaxis-for-patients-receiving-docetaxel-cyclophosphamide-chemotherapy-for-breast-cancer-a-systematic-review
#12
REVIEW
Ricardo Fernandes, Sasha Mazzarello, Carol Stober, Lisa Vandermeer, Shaan Dudani, Mohamed F K Ibrahim, Habeeb Majeed, Kirstin Perdrizet, Risa Shorr, Brian Hutton, Dean Fergusson, Mark Clemons
BACKGROUND: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address this knowledge gap. METHODS: Embase, Ovid Medline, Pubmed, the Cochrane database of systematic reviews, and Cochrane register of controlled trials were searched from 1946 to April 2016 for studies evaluating primary prophylactic FN treatments in breast cancer patients receiving DC chemotherapy...
October 25, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27774364/pancytopenia-and-severe-gastrointestinal-toxicities-associated-with-5-fluorouracil-in-a-patient-with-thymidylate-synthase-tyms-polymorphism
#13
Bo Wang, Shannon J Walsh, Muhammad W Saif
5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in solid tumors, including colon, gastric and breast cancers. The pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency leading to severe toxicity after administration of 5-flourouracil (5-FU) and capecitabine has been well-recognized. However, the data about the association of the target enzyme, thymidylate synthase (TYMS) with the toxicity of these agents is limited. A 50-year-old Caucasian woman with T2N2M0 Stage IIIB squamous cell rectal cancer after local surgical excision initiated 5-FU therapy with mitomycin-C and radiation therapy in the adjuvant setting...
September 21, 2016: Curēus
https://www.readbyqxmd.com/read/27751704/when-hydromorphone-is-not-working-try-loratadine-an-emergency-department-case-of-loratadine-as-abortive-therapy-for-severe-pegfilgrastim-induced-bone-pain
#14
Katherine Moore, Rachel Haroz
BACKGROUND: Intractable bone pain is a notorious adverse effect of granulocyte-colony stimulating factors (G-CSFs), such as pegfilgrastim and filgrastim, which are given to help prevent neutropenia in patients who are undergoing chemotherapy. G-CSF-induced bone pain is surprisingly common and often refractory to treatment with conventional analgesics. CASE REPORT: This article describes an emergency department case of opiate and nonsteroidal anti-inflammatory drug-resistant pegfilgrastim-induced bone pain that was successfully alleviated with 10 mg of oral loratadine, allowing for discharge home...
October 14, 2016: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27688102/partner-an-open-label-randomized-phase-2-study-of-docetaxel-cisplatin-chemotherapy-with-or-without-panitumumab-as-first-line-treatment-for-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#15
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, Rita Axelrod, Douglas Adkins, Shubham Pant, Paul O'Brien, Philip R Debruyne, Kelly S Oliner, Jun Dong, Swami Murugappan
OBJECTIVE: This phase 2 estimation study evaluated docetaxel/cisplatin with/without panitumumab, an anti-epidermal growth factor receptor monoclonal antibody, as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Randomized patients received docetaxel/cisplatin (75mg/m(2) each) with/without panitumumab (9mg/kg) in 21-day cycles. Patients randomized to panitumumab+chemotherapy could continue panitumumab monotherapy after completing six chemotherapy cycles without progression; patients randomized to chemotherapy alone could receive second-line panitumumab after progression...
October 2016: Oral Oncology
https://www.readbyqxmd.com/read/27649817/feasibility-and-kinetics-of-cd34-hematopoietic-progenitor-cell-mobilization-in-response-to-a-single-administration-of-docetaxel-chemotherapy-and-pegfilgrastim-in-a-contemporary-cohort-of-patients-with-metastatic-breast-cancer
#16
Harminder Takhar, Anna Rachelle Mislang, Nimit Singhal, Michael P Brown
AIM: Autologous hematopoietic stem cell transplantation (auto-HSCT) remains an experimental therapy for metastatic breast cancer (MBC) and there is no established protocol for cluster of differentiation 34(+) (CD34(+) ) hematopoietic progenitor cell (HPC) mobilization with historic studies using growth factors with or without chemotherapy. This study describes the feasibility and kinetics of CD34(+) HPC mobilization following a single administration of docetaxel and the pegylated form of recombinant human granulocyte colony-stimulating factor analogue filgrastim (pegfilgrastim)...
September 21, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27647222/safety-and-efficacy-of-dose-dense-chemotherapy-with-tcf-regimen-in-elderly-patients-with-locally-advanced-or-metastatic-gastric-cancer
#17
Wanda Liguigli, Gianluca Tomasello, Laura Toppo, Rossana Poli, Silvia Lazzarelli, Federica Negri, Bruno Perrucci, Alessandra Curti, Matteo Brighenti, Gianvito Donati, Morena Nazzari, Mario Martinotti, Marco Vismarra, Massimo Rovatti, Rodolfo Passalacqua
PURPOSE: To evaluate the efficacy and safety of dose-dense TCF in elderly (≥65 years) compared to younger patients. METHODS: Safety and efficacy data relative to 119 consecutive patients with locally advanced or metastatic gastric cancer treated at our institution and enrolled in different phase II trials were retrospectively collected. All patients were treatment-naive and received docetaxel 70 mg/m2 day 1, cisplatin 60 mg/m2 day 1, l-folinic acid 100 mg/m2 days 1-2, followed by 5-fluorouracil 400 mg/m2 bolus days 1-2, and then 600 mg/m2 as a 22-hour continuous infusion days 1-2, every 14 days, plus pegfilgrastim 6 mg on day 3...
August 23, 2016: Tumori
https://www.readbyqxmd.com/read/27628549/-the-clinical-utility-of-pegfilgrastim-in-combination-with-adjuvant-fec-100-and-tc-chemotherapy-for-breast-cancer
#18
Hirotsugu Yanai, Kayoko Endo, Mayumi Matsumoto, Masanori Kon, Tomoharu Sugie
BACKGROUND: More than 20%of breast cancer patients who undergo myelosuppressive chemotherapy involving FEC(100) or TC experience febrile neutropenia(FN), and pegfilgrastim is commonly recommended as the primary prophylaxis. Delays and/or dose-reductions in chemotherapy should be avoided as much as possible to maximize the clinical benefits of these adjuvant chemotherapies. PURPOSE: This study assessed the relative dose intensity(RDI), efficacy, and safety of pegfilgrastim in patients with breast cancer...
September 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27621310/long-term-use-of-pegfilgrastim-in-children-with-severe-congenital-neutropenia-clinical-and-pharmacokinetic-data
#19
Francesca Fioredda, Tiziana Lanza, Federica Gallicola, Francesca Riccardi, Marina Lanciotti, Elena Mastrodicasa, Sara Signa, Sabrina Zanardi, Michaela Calvillo, Carlo Dufour
No abstract text is available yet for this article.
September 12, 2016: Blood
https://www.readbyqxmd.com/read/27572552/cost-effectiveness-of-febrile-neutropenia-prevention-with-primary-versus-secondary-g-csf-prophylaxis-for-adjuvant-chemotherapy-in-breast-cancer-a-systematic-review
#20
REVIEW
T Younis, D Rayson, S Jovanovic, C Skedgel
The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its "value for money". This systematic review examined (i) cost-effectiveness of PP versus SP, (ii) FN threshold at which PP is cost-effective including the guidelines 20 % threshold and (iii) potential impact of G-CSF efficacy assumptions on outcomes. The systematic review identified all cost-effectiveness/cost-utility analyses (CEA/CUA) involving PP versus SP G-CSF for AC in BC that met predefined inclusion/exclusion criteria...
October 2016: Breast Cancer Research and Treatment
keyword
keyword
37851
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"